Abstract: A vehicle includes a chassis, a front axle assembly coupled to the chassis, a rear axle assembly coupled to the chassis, a powertrain coupled to the chassis, the powertrain including an engine, an engine air intake coupled to the engine to provide clean air to the engine, an exhaust system coupled to the engine to expel a flow of exhaust gases from the engine, and a suction conduit extending between the exhaust system and the engine air intake.

Abstract: A motion control system includes a top mount, a bottom mount, a rigid housing, an air spring, and a linear actuator. The air spring transfers force of a first load path between the top mount and the bottom mount. The air spring includes a pressurized cavity containing pressurized gas that transfers the force of the first load path. The linear actuator transfers force of a second load path between the top mount and the bottom mount in parallel to the first load path. The rigid housing defines at least part of the pressurized cavity and transfers the force of the second load path.

Abstract: The invention relates, in certain aspects, to developable forms of certain compounds that are useful to treat and/or prevent EBV infection and related conditions in a subject. The invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.

Abstract: A vehicle includes a chassis, a front axle coupled to the chassis, a rear axle coupled to the chassis, a powertrain coupled to the chassis, a cab coupled to the chassis, a rear module coupled to the chassis behind the cab. The powertrain is configured to drive at least one of the front axle or the rear axle. The rear module is selectively reconfigurable between a plurality of configurations.

Abstract: The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.

Abstract: Strength training apparatuses and methods therefor. The strength training apparatus includes a frame, first and second swing arms pivotally coupled to the frame and extending from the frame above a weight bench, and a user's platform armrest (UPA) releasably secured to and spanning between the swing arms. The UPA is configured to support a user's upper arms while the user is lying supine on the weight bench underneath the UPA. An angular adjusting mechanism located below a horizontal plane of the weight bench is configured to adjust an angle of the swing arms relative to the frame while the UPA is coupled to the swing arms. A platform adjusting mechanism located within the user's platform armrest is configured to adjust a position of the UPA along the swing arms while the UPA is coupled to the swing arms.